122 related articles for article (PubMed ID: 38570701)
1. Author Correction: A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas.
Cerchietti LC; Lopes EC; Yang SN; Hatzi K; Bunting KL; Tsikitas LA; Mallik A; Robles AI; Walling J; Varticovski L; Shaknovich R; Bhalla KN; Chiosis G; Melnick A
Nat Med; 2024 May; 30(5):1503. PubMed ID: 38570701
[No Abstract] [Full Text] [Related]
2. A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas.
Cerchietti LC; Lopes EC; Yang SN; Hatzi K; Bunting KL; Tsikitas LA; Mallik A; Robles AI; Walling J; Varticovski L; Shaknovich R; Bhalla KN; Chiosis G; Melnick A
Nat Med; 2009 Dec; 15(12):1369-76. PubMed ID: 19966776
[TBL] [Abstract][Full Text] [Related]
3. A purine scaffold HSP90 inhibitor BIIB021 has selective activity against KSHV-associated primary effusion lymphoma and blocks vFLIP K13-induced NF-κB.
Gopalakrishnan R; Matta H; Chaudhary PM
Clin Cancer Res; 2013 Sep; 19(18):5016-26. PubMed ID: 23881928
[TBL] [Abstract][Full Text] [Related]
4. HSP90 inhibitor (NVP-AUY922) enhances the anti-cancer effect of BCL-2 inhibitor (ABT-737) in small cell lung cancer expressing BCL-2.
Yang H; Lee MH; Park I; Jeon H; Choi J; Seo S; Kim SW; Koh GY; Park KS; Lee DH
Cancer Lett; 2017 Dec; 411():19-26. PubMed ID: 28987383
[TBL] [Abstract][Full Text] [Related]
5. Hsp90 inhibition by PU-H71 induces apoptosis through endoplasmic reticulum stress and mitochondrial pathway in cancer cells and overcomes the resistance conferred by Bcl-2.
Gallerne C; Prola A; Lemaire C
Biochim Biophys Acta; 2013 Jun; 1833(6):1356-66. PubMed ID: 23485394
[TBL] [Abstract][Full Text] [Related]
6. Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90.
He H; Zatorska D; Kim J; Aguirre J; Llauger L; She Y; Wu N; Immormino RM; Gewirth DT; Chiosis G
J Med Chem; 2006 Jan; 49(1):381-90. PubMed ID: 16392823
[TBL] [Abstract][Full Text] [Related]
7. The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1.
Usmani SZ; Bona RD; Chiosis G; Li Z
J Hematol Oncol; 2010 Oct; 3():40. PubMed ID: 20977755
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90.
Llauger L; He H; Kim J; Aguirre J; Rosen N; Peters U; Davies P; Chiosis G
J Med Chem; 2005 Apr; 48(8):2892-905. PubMed ID: 15828828
[TBL] [Abstract][Full Text] [Related]
9. Hsp90 inhibitor 17-AAG sensitizes Bcl-2 inhibitor (-)-gossypol by suppressing ERK-mediated protective autophagy and Mcl-1 accumulation in hepatocellular carcinoma cells.
Wang B; Chen L; Ni Z; Dai X; Qin L; Wu Y; Li X; Xu L; Lian J; He F
Exp Cell Res; 2014 Nov; 328(2):379-87. PubMed ID: 25196280
[TBL] [Abstract][Full Text] [Related]
10. Purine-scaffold Hsp90 inhibitors.
Chiosis G; Tao H
IDrugs; 2006 Nov; 9(11):778-82. PubMed ID: 17096299
[TBL] [Abstract][Full Text] [Related]
11. Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase.
Chiosis G; Lucas B; Shtil A; Huezo H; Rosen N
Bioorg Med Chem; 2002 Nov; 10(11):3555-64. PubMed ID: 12213470
[TBL] [Abstract][Full Text] [Related]
12. Discovery and development of purine-scaffold Hsp90 inhibitors.
Chiosis G; Kang Y; Sun W
Expert Opin Drug Discov; 2008 Jan; 3(1):99-114. PubMed ID: 23480142
[TBL] [Abstract][Full Text] [Related]
13. Expression of CD95 antigen and Bcl-2 protein in non-Hodgkin's lymphomas and Hodgkin's disease.
Nguyen PL; Harris NL; Ritz J; Robertson MJ
Am J Pathol; 1996 Mar; 148(3):847-53. PubMed ID: 8774139
[TBL] [Abstract][Full Text] [Related]
14. Expression of bcl-2 oncogene product in primary non-Hodgkin's malignant lymphoma of the oral cavity.
Takahashi H; Kawazoe K; Fujita S; Okabe H; Hideshima K; Tsuda N; Tezuka F
Pathol Res Pract; 1996 Jan; 192(1):44-53. PubMed ID: 8685041
[TBL] [Abstract][Full Text] [Related]
15. DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas.
He Y; Koch R; Budamagunta V; Zhang P; Zhang X; Khan S; Thummuri D; Ortiz YT; Zhang X; Lv D; Wiegand JS; Li W; Palmer AC; Zheng G; Weinstock DM; Zhou D
J Hematol Oncol; 2020 Jul; 13(1):95. PubMed ID: 32677976
[TBL] [Abstract][Full Text] [Related]
16. HSP90 inhibition results in apoptosis of Philadelphia acute lymphoblastic leukaemia cells: an attractive prospect of new targeted agents.
Tavernier E; Flandrin-Gresta P; Solly F; Rigollet L; Cornillon J; Augeul-Meunier K; Stephan JL; Montmartin A; Viallet A; Guyotat D; Campos L
J Cancer Res Clin Oncol; 2012 Oct; 138(10):1753-8. PubMed ID: 22706881
[TBL] [Abstract][Full Text] [Related]
17. Molecular analysis of the BCL-3 locus at chromosome 17q22 in B-cell neoplasms.
Yano T; Sander CA; Andrade RE; Gauwerky CE; Croce CM; Longo DL; Jaffe ES; Raffeld M
Blood; 1993 Sep; 82(6):1813-9. PubMed ID: 8400234
[TBL] [Abstract][Full Text] [Related]
18. Bcl-2 and bax protein expression in indolent versus aggressive B-cell non-Hodgkin's lymphomas.
Wheaton S; Netser J; Guinee D; Rahn M; Perkins S
Hum Pathol; 1998 Aug; 29(8):820-5. PubMed ID: 9712423
[TBL] [Abstract][Full Text] [Related]
19. [Diagnostic and therapeutic values of interphase fluorescence in situ hybridization in B-cell lymphomas: a clinicopathologic analysis of 604 cases].
Chen M; Yang JL; Zhao S; Liu WP; Li GD; Ye YX; Yan JQ; Zhang WY
Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):920-925. PubMed ID: 30522172
[No Abstract] [Full Text] [Related]
20. [B-cell lymphomas with concurrent myc and bcl-2/IgH or bcl-6 translocations].
Luo DL; Liu YH; Zhang F; Xu FP; Yan LX; Chen J; Xu J; Luo XL; Zhuang HG
Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):584-8. PubMed ID: 24314242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
